Biolase, Inc. · OTC:BIOLQ

Biolase — Biolase Technology — Shareholder Meeting (May 2011)

30 slides from Biolase's shareholder meeting presentation, May 5, 2011

  1. Slide 1: Annual Shareholder Meeting

    Biolase Technology, Inc. Annual Shareholder Meeting May 5, 2011, Irvine, California Federico Pignatelli, CEO, Chairman, and Shareholder

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management's beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "e

  3. Slide 3: Redefining Surgery in Dentistry and Medicine

    Redefining Surgery in Dentistry and Medicine Conventional Surgical Devices: Scalpel, High Speed Drill, Electrosurge, Electric Bone Saws and Heat Generating Lasers How BIOLASE Changes That? The Science of WaterLase Years of engineering and research at BIOLASE led to the discovery that the 2,780 nm wa

  4. Slide 4: Why BIOLASE WaterLase Technology in Dentistry?

    Why BIOLASE WaterLase Technology in Dentistry?

  5. Slide 5: Traditional Dentistry

    Traditional Dentistry Traditional Dentistry

  6. Slide 6: Progressive & Biological Hi-Tech Dentistry

    5/5/2011 PAGE 6 Progressive & Biological Hi-Tech Dentistry Atraumatic Pediatric Tooth Extraction The aiming beam on the NEW WaterLase iPlus is green. This red beam featured in the previous generation of WaterLase products does not cut the tissue. Tissue is cut biologically, with water at the molecul

  7. Slide 7: Making Dentistry Less Frightening

    Making Dentistry Less Frightening Traditional Surgical Approach: Using the dental drill offers more of the same which is pain, local anesthetic, swelling, pain killers, micro-fractures and the potential for cross contamination. Progressive and Hi-tech Surgical Approach: Using WaterLase technology of

  8. Slide 8: Technology Supported by Scientific Data

    Technology Supported by Scientific Data 5/5/2011 PAGE 8 Substantial Data: The effectiveness of dental lasers is proven and well researched. Clinical data and peer- reviewed specialty journals substantiate the effectiveness of laser treatment in a wide variety of procedures.

  9. Slide 9: Dental Schools Teaching WaterLase Technology

    Some of the Dental Schools that are Teaching WaterLase Technology around the World

  10. Slide 10: WaterLase High Speed Cutting

    WaterLase High Speed Cutting 5/5/2011 PAGE 10

  11. Slide 11: WaterLase vs. Drill

    WaterLase vs. Drill 5/5/2011 PAGE 11

  12. Slide 12: Why WaterLase Technology?

    Why WaterLase Technology? Because NO Pain, NO Tissue Damage & NO Risk of Cross-Contamination: WaterLase MD(tm) reduced E. faecalis 2.86 times more effectively than NaOCl3 1. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Co

  13. Slide 13: Patent Portfolio

    Current Status: BIOLASE currently has 286 issued and pending patents, 70% of which are related to our core Er;Cr:YSGG technology and medical lasers. Filing costs and maintenance are closely monitored. Funding for redundant patents and patents with a low-probability for issuance are stopped. Patent P

  14. Slide 14: Intellectual Property

    Paths to monetization: Internal development, licensing, and legal action against infringers. Analyses by IP rating firms and management have identified patent families with the greatest potential: Ophthalmology, specifically a medical treatment for Presbyopia, laser toothbrush, and flavored and ster

  15. Slide 15: Foundation for a Rapid Recovery

    Why a turnaround of BIOLASE today will be quicker and more effective than in the past: BIOLASE has a better organizational structure, better cost control, and more efficient & effective management than ever before. The BIOLASE brand is currently known by over 80% of North American dentists and is gr

  16. Slide 16: How BIOLASE is Positioned

    How BIOLASE is Positioned BIOLASE United States BIOLASE International Total: 12,200 Total: 5,100 Grand Total: 17,300 (CHART) (CHART) 2,700 2,400 5,500 6,700

  17. Slide 17: Owning the Hard Tissue Dental Laser Market

    Owning BIOLASE Means Owning the Hard Tissue Dental Laser Market... Biolase 80% Source: Biolase Technology Licensing Reports 5/5/2011 PAGE 17

  18. Slide 18: The Overall Dental Laser Market

    ....and the Overall Dental Laser Market. Biolase 45% Source: iData Research Inc. 5/5/2011 PAGE 18 2009 US Dental Laser Market: Hard & Soft Tissue

  19. Slide 19: Our Market Opportunity

    Our Market Opportunity BIOLASE's current market penetration is less than 1.5% of the potential global market. 176,000 dentists in the US and Canada.1 Over 1.2 million dentists in 134 countries.2 17,300 systems in over 10,000 practices. Every 1% of further market penetration is equal to an opportunit

  20. Slide 20: The Untapped Portion of the Market

    The Untapped Portion of the Market How BIOLASE WaterLase technology can increase new patients by 33%. According to the ADA...nearly 25% of all Americans avoid dentists because they are afraid of dental drills and needles. There are 160,000 dentists currently serving a population of 300 million Ameri

  21. Slide 21: Global Opportunity in Emerging Dental Markets

    Global Opportunity in Emerging Dental Markets North America 176,000 dentists 1 dentist / 1,900 population Western Europe 240,000 dentists 1 dentist / 1,800 population Latin America 298,000 dentists 1 dentist / 5,600 population Eastern Europe 120,000 dentists 1 dentist / 4,000 population Middle East

  22. Slide 22: Emerging Market Opportunities

    Emerging Market Opportunities 5/5/2011 PAGE 22 Private Dental Office in China. California Suburb? No...China.

  23. Slide 23: The Value of Technology

    The Value of Technology 5/5/2011 PAGE 23 Dental Lasers: Allows dentists to perform their current daily procedures more efficiently plus perform a wide variety of dental procedures they otherwise may be referring out of their practices. Cone Beam 3-D Dental Imaging: Provides a high-definition, digita

  24. Slide 24: Ophthalmology and Medical

    Ophthalmology: BIOLASE currently holds 10 issued and 19 pending U.S. and International patents in four patent families in the field ophthalmology. These patents give BIOLASE a wide range of applications and coverage in the field. Management is currently evaluating spinning- off of this technology in

  25. Slide 25: Current Line of BIOLASE Products

    Current Line of BIOLASE Products 5/5/2011 PAGE 25 All-tissue dental lasers: Our all-tissue lasers include our new flagship laser, the revolutionary WaterLase iPlus and the WaterLase MD Turbo, an entry level all-tissue laser. Diode soft-tissue dental lasers: Our soft tissue lasers include the ezLase

  26. Slide 26: Global Leader in Dental Lasers

    Global Leader in Dental Lasers Over 16,000 laser systems sold to over 10,000 dental practices in over 50 countries worldwide. We have over 160 employees worldwide We have sales offices in the U.S., Floss (Germany), Madrid (Spain) and Shanghai (China) with expansion planned in Mumbai (India), Dubai (

  27. Slide 27: Operations

    Operations 5/5/2011 PAGE 27 Manufacturing and Research & Development Our 57,000 sq. ft. facility houses administrative, sales, marketing, customer care, R&D and manufacturing. It is ISO 9001 certified and FDA GMP with clean room operations. Nearly 100% of our components and subassemblies are manufac

  28. Slide 28: Management & Employee Stakeholders

    Management and Employees: BIOLASES's entire executive team holds options to purchase common stock. Further, in December 2010, the Board of Directors granted approximately 1.5 million stock options to ALL of the employees of the Company. These options have a strike price of $2 and have made all emplo

  29. Slide 29: Chart & Financial History

    5/5/2011 PAGE 29 Volume: Millions of Shares 0.5 1.0 Chart & Financial History 20 15 10 5 BLTI SHARE PRICE Guidance 62.5 1994-2006 Pignatelli Chairman of the Board Exclusive distribution partnership with Henry Schein Aug 2006-Aug 2010 Aug 2010-Present Pignatelli CEO & Board Chairman 1998 FDA Clearanc

  30. Slide 30: BT! wOLASETecmabgr $5523 soe coon 150.0%

    BT! wOLASETecmabgr $5523 0 soe coon 150.0% Gh olgteraotne sos 27TH me OH %—FrotersGamble «hE 23 HHT KBR pir FalomaresTeeh 8983701 aoe 808 GR werame 82 =e BIOLASE

Biolase Technology — Shareholder Meeting (May 2011) on 6ix